Clinical survival analysis suggests that the poor prognosis of patients with NSCLC is correlated with high expression of S1PR1, S1PR2, S1PR3, and S1PR5, suggesting that S1PR targeting through Fingolimod might be relevant in n NSCLC models. Here, S1PR1 is linked to non-small cell lung carcinoma.